1. Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2
- Author
-
Takahiro Kageyama, Shigeru Tanaka, Keishi Etori, Koto Hattori, Kazusa Miyachi, Tadamichi Kasuya, Taro Iwamoto, Kei Ikeda, Hidetoshi Igari, Koutaro Yokote, and Hiroshi Nakajima
- Subjects
Vaccines, Synthetic ,COVID-19 Vaccines ,General Veterinary ,General Immunology and Microbiology ,SARS-CoV-2 ,Public Health, Environmental and Occupational Health ,COVID-19 ,CD8-Positive T-Lymphocytes ,Antibodies, Viral ,Infectious Diseases ,Antibody Formation ,Leukocytes, Mononuclear ,Humans ,Molecular Medicine ,mRNA Vaccines ,BNT162 Vaccine - Abstract
Predictive clinical factors associated with favorable responses to BNT162b2 mRNA vaccine against SARS-CoV-2 have been reported in some studies; however, there is a subgroup with low antibodytiters without well-known clinical factors reducing antibody responses. To clarify the immunological backgrounds that underlie the difference in antibody responses, we analyzed peripheral blood mononuclear cells (PBMCs) of each 20 individuals with a high anti-SARS-CoV-2 antibody titer and a low antibody titer out of 1774 healthcare workers who received BNT162b2 mRNA vaccine. A higher percentage of B cells before vaccination was associated with a higher antibody titer. Among B cells, naïve and transitional B cell frequencies were positively correlated with a higher antibody titer, whereas the frequencies of late memory B cells and plasmablasts were associated with a lower antibody titer. Fold change in the frequency of activated CD8
- Published
- 2022
- Full Text
- View/download PDF